Skip to Main Content

Schizophrenia Inpatient – Maplight-007C-MA

About the Study

For adults with schizophrenia who warrant inpatient hospitalization.

The goal of this study is to assess the efficacy, safety, and tolerability of ML-007C-MA compared with placebo in reducing symptoms of schizophrenia in adults experiencing an acute exacerbation of psychosis.

This study is sponsored by Maplight Therapeutics.

Eligibility

You may be eligible to participate in this study if you:

  • are between the ages of 18-64 years old

  • meet DSM-5 criteria for schizophrenia or schizoaffective disorder

  • are currently experiencing an acute exacerbation of psychosis

  • are willing to stay in our overnight 24-hour observation unit for the full length of the study

If chosen for this study, you will be compensated for every study visit that you complete and we can provide transportation if needed.

If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.